21st Century Investor Relations, Inc (21ST) has received fees for services for the creation, preparation and distribution of materials, including information presented on this website, from Viral Genetics, paid by Imperial Consulting Network (see ICN Compensation below) in the amount of twelve-thousand dollars upfront and twenty-five hundred dollars per month for six-months, plus two hundred fifty thousand shares of restricted stock. 21ST is paid editorial fees for its writing and dissemination of materials, and the companies featured do not have to meet any specific financial criteria. The clients represented by 21ST are typically development-stage companies that pose a much higher risk to investors. When investing in a speculative stock of this nature, it is possible to lose your entire investment over time. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products, the company’s ability to fund its capital requirements in the near term and in the long term, pricing pressures, etc. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives goals, assumptions or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur. This is not an offer to buy or sell securities. Information or opinions presented are solely for informative purposes and are not intended nor should they be construed as investment advice. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov , FINRA at www.finra.org , Pink OTC Markets, Inc, www.pinksheets.com. Information contained on this website is not a complete study of the featured Company. Information used and statements of fact have been obtained from the featured Company and other sources, but not verified nor guaranteed by 21ST as to completeness or accuracy. Such information is subject to change without notice. It should be understood that there is no guarantee past performance will be indicative of future results. Opinions stated herein may be solely 21ST’s, and not necessarily those of the featured Company. Officers, directors, and employees of 21ST or their families, may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. Trademarks are the property of their respective owners. ©2010 21st Century Investor Relations, Inc. All rights reserved.
ICN Compensation-in October 2008, Viral Genetics entered into a non-exclusive Marketing/ Publications Agreement with Imperial Consulting Network (“ICN”) to provide an awareness program in the investment and financial community for Viral Genetics as well as providing introductions to professionals that would be useful to the Company. The agreement expired December 31, 2009. Consideration paid upon the achievement of defined milestones (specified selling price per share in the OTC-BB or Pink Sheets) in the form of shares of the Company’s common stock and two year common stock purchase warrants to purchase shares of common stock at $.03 per share. Pursuant to this agreement, Viral Genetics expensed $848,000 of stock based compensation (issuance of 15 million shares and warrants to purchase 6 million shares of common stock at $.03 per share, expiring November 3, 2011 was incurred in 2009.
Viral Genetics and ICN entered into another agreement expiring December 31, 2010 with comparable terms and conditions. Under the Agreement, ICN is entitled to receive 4 million shares at execution. Viral Genetics calculated these shares at fair market value of $200,000. Up to an additional an additional 15 million common shares and three year common purchase warrants to purchase an additional 12 million common shares at prices ranging from $.03-$.05 per share could be issuable upon achievement of defined milestones (specified selling price per share in the OTC-BB or Pink Sheets)
Disclaimer. This profile release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. None of Viral Genetics’ drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies, including VGV-X, VGV-L, and VGV-S, in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
================================================
Going Concern Statements.
We would like to point out that the majority of companies listed on the OTC Bulletin Board have factors which create an uncertainty about the their ability to continue as a going concern. These concerns are typically related to financing (or lack of), competitive environments, lack of operating history and operating at loss levels which is typical of most start-ups. These statement can usually be found in their most recent 10Q filings and typically you don’t have to dig to far down past the financial tables. We like to use http://www.pinksheets.com for quick and easy access to SEC filings. We think it would be wise for most investors to assume that all companies listed on the OTC Bulletin Board (and many on NASDAQ) have going concern issues.
================================================
Disclaimer: Important Distinction #1. First and foremost the Initial Profile Coverage is not a buy recommendation. Meaning that there will be no buys or sales issued by 21st Century Investor Relations. If this was a buy recommendation, you can rest assured that we would crank up our Public Relations arm into high gear, full speed ahead and damn the torpedoes to make everyone know just how brilliant we were when we issued the list. Interviews on CNBC, articles in Barron’s and accolades in the Wall Street Journal—the only thing we love more than money is praise and fame–but it just isn’t going to happen. What the 21st Century Investor Relations is…is a “news aggregation and Micro-cap marketing service”. With the advent of 21st Century Investor Relations, everyone knows what that term means. What it means to us is the following: We will follow the progress of as many Micro-cap related publicly traded stocks as humanly possible (The large, the small and the minuscule) and advise you of when they have reported news. As a subscriber to 21st Century Investor Relations, this means you will be able to broadly follow the entire industry right from a single e-mail. We will report who released news and point (with hyper links) to where the news can be found. We try to use Yahoo! Finance as extensively as possible so we don’t send you all over cyberspace. We love Yahoo, you will too. Any decisions as to buy or sell however, are strictly up to you. Which leads to important distinction #2. How do we get paid? 21st Century Investor Relations is an IR firm that specializes in getting (or creating) coverage for publicly traded companies through proprietary Internet marketing techniques. As such, is important to note that anytime we say anything about a company, it is because the company is a client of our parent company, or because we would like them to be a client of our parent company. In a nutshell, you can throw out any thoughts of us being even a little bit impartial. It just ain’t gonna happen. We love everyone. 21st Century Investor Relations. is an independent research and investor-relations consulting firm that publishes investment-research reports on selected companies. While it is its intent to identify and research companies that it believes might prove to be profitable investments, 21st Century Investor Relations is not liable for any investment decisions by its readers. 21st Century Investor Relations represent a solicitation to buy or sell the securities discussed within the report. It is strongly recommended that any purchase or sale decisions be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. The information contained herein is provided as an information service only and is based upon sources deemed reliable, but not guaranteed by The 21st Century Investor Relations.
Past performance of previously featured companies does not guarantee the future success of any currently featured or mentioned company. The information contained herein is subject to change without notice, and The 21st Century Investor Relations assumes no responsibility to update the information in this or any report published. Use of this or any report published by The 21st Century Investor Relations may be subject to the applicable rules of certain self-regulatory organizations and the securities mentioned herein, which are traded Over The Counter, and may not be cleared for sale in certain states. The 21st Century Investor Relations and/or its employees, officers, affiliates or members of their families may have long or short positions in any of the securities discussed in this or other reports published herein (and/or options or warrants relating thereto) and may purchase and or sell these securities, options or warrants from time to time in the open market or otherwise. The 21st Century Investor Relations may derive compensation through research services and subscriptions and/or investor-relations consulting from the companies featured or mentioned in its reports. Write or call The 21st Century Investor Relations for disclosure details as required by Rule 17b as it relates to individual issues. In no event shall 21st Century Investor Relations report be liable for direct, indirect, incidental or consequential damages resulting from the use of this information. 21st Century Investor Relations shall be indemnified and held harmless from any actions, claims, proceedings or liabilities with respect to the information herein. 21st Century Investor Relations is not a securities broker-dealer, investment advisor or a securities exchange and is not registered as such with the Securities and Exchange commission nor any state securities regulation authority. Readers of this e-mail newsletter should recognize that the 21st Century Investor Relations is only providing a delivery service to electronically transmit information to potential investors. In this respect, the 21st Century Investor Relations is no different than the provider of any other delivery service such as the United States Post Office or any other express delivery service. Accordingly, investors should be aware that 21st Century Investor Relations has not evaluated nor investigated any of the companies listed in this e-mail to determine their merit or the risk of investment in any such company. 21st Century Investor Relations does not endorse any company listed herein and the 21st Century Investor Relations does not represent that the information contained in any offering documents states all material facts or does not omit a material fact necessary to make the
